- Conditions
- Coronary Artery Disease
- Interventions
- Microport Firehawk stent, 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)
- Device
- Lead sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • La Jolla, California + 38 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Myocardial Infarction
- Interventions
- Single Vessel Disease, Multi-vessel Disease, Culprit Vessel Only, Multi-vessel Disease, Complete Revascularization, Medtronic Resolute family of stents, Volcano based pressure wires Verrata, Verrata Plus and any subsequent marketed Volcano pressure wire technology, Terumo Glidesheath Slender, Terumo TR Band Radial Compression Device
- Device · Procedure
- Lead sponsor
- David Kong, M.D.
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 427 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina